Community Research Initiative of New England

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Pilot Study of Treating HCV at a Psychiatrist-staffed Outpatient Addiction Clinic

Phase 4

Completed

Conditions: Hepatitis C, Chronic
Opiate Dependence
Hepatitis C

Interventions: Drug: sofosbuvir/velpatasvir

First Posted Date: 2017-08-01

Last Posted Date: 2021-05-13

Lead Sponsor: Community Research Initiative of New England

Target Recruit Count: 11

Registration Number: NCT03235154

Locations: 🇺🇸
Cambridge Health Alliance Outpatient Addiction Services, Somerville, Massachusetts, United States

A Pilot Study to Determine if Raltegravir Eradicates HIV From Peripheral Blood Mononuclear Cells

Phase 4

Withdrawn

Conditions: HIV Infections
Acquired Immune Deficiency Syndrome

Interventions: Drug: Raltegravir plus Truvada
Drug: Atripla

First Posted Date: 2010-08-02

Last Posted Date: 2017-06-14

Lead Sponsor: Community Research Initiative of New England

Registration Number: NCT01173510

BATAR: Individuals Currently Taking Boosted Atazanavir as Part of an HIV Treatment Regimen Will be Evaluated to See if Substituting Raltegravir for Nucleoside Transcriptase Inhibitors Will be Safe and Well Tolerated.

Phase 4

Completed

Conditions: HIV

Interventions: Drug: atazanavir/raltegravir
Drug: atazanavir/tenofovir/emtricitabine

First Posted Date: 2009-07-02

Last Posted Date: 2017-07-21

Lead Sponsor: Community Research Initiative of New England

Target Recruit Count: 43

Registration Number: NCT00931801

Locations: 🇺🇸
Spectrum Medical Group, Phoenix, Arizona, United States
🇺🇸
Treasure Coast Infectious Disease Consultants, Vero Beach, Florida, United States
🇺🇸
Christi Research, Wichita, Kansas, United States

and more 6 locations

Lopinavir/r or Fosamprenavir/r Switch to Atazanavir/r or Darunavir/r

Phase 4

Completed

Conditions: HIV Infections

Interventions: Drug: DRV/r
Drug: ATV/r

First Posted Date: 2008-09-22

Last Posted Date: 2017-08-21

Lead Sponsor: Community Research Initiative of New England

Target Recruit Count: 49

Registration Number: NCT00756730

Locations: 🇺🇸
Community Research Initiative, Boston, Massachusetts, United States
🇺🇸
Abbott Northwestern Infectious Disease and Travel Clinic, Minneapolis, Minnesota, United States
🇺🇸
Nicholaos C. Bellos, MD, PA, Dallas, Texas, United States

and more 8 locations

BRAVO: Background Regimen of Raltegravir on Virologic Outcome

Completed

Conditions: HIV Infections

Interventions: Drug: raltegravir

First Posted Date: 2008-09-12

Last Posted Date: 2017-07-02

Lead Sponsor: Community Research Initiative of New England

Target Recruit Count: 442

Registration Number: NCT00751530

Locations: 🇺🇸
Dr. Nicholaos C. Bellos & Associates, Dallas, Texas, United States
🇺🇸
Light Source Medical, Los Angeles, California, United States
🇺🇸
Quest Clinical Research, San Francisco, California, United States

and more 12 locations

Efficacy Study of Substitution of Darunavir/Ritonavir (DRV/r) for Dual-boosted Protease Inhibitors

Phase 4

Completed

Conditions: HIV Infections

Interventions: Drug: continue on current dual boosted PI
Drug: Darunavir (DRV/r)

First Posted Date: 2007-10-12

Last Posted Date: 2017-07-21

Lead Sponsor: Community Research Initiative of New England

Target Recruit Count: 24

Registration Number: NCT00543101

Locations: 🇺🇸
Community Research Initiative of New England, Boston, Massachusetts, United States
🇺🇸
Albany Medical Center, Albany, New York, United States
🇺🇸
Orlando Immunology Center, Orlando, Florida, United States

and more 2 locations

BOOST: Study of Increased Dosage of Lopinavir/Ritonavir (LPV/r)

Phase 4

Terminated

Conditions: HIV Infections

First Posted Date: 2006-12-21

Last Posted Date: 2010-12-08

Lead Sponsor: Community Research Initiative of New England

Registration Number: NCT00414284

Locations: 🇺🇸
Community Research Initiative of New England - Boston, Boston, Massachusetts, United States

FOTO: Five Consecutive Days on Treatment With Efavirenz, Tenofovir, and Emtricitabine Followed by Two Days Off Treatment Versus Continuous Treatment

Phase 4

Completed

Conditions: HIV Infections

Interventions: Drug: Intermitent Dosing

First Posted Date: 2006-12-21

Last Posted Date: 2017-09-25

Lead Sponsor: Community Research Initiative of New England

Target Recruit Count: 60

Registration Number: NCT00414635

Locations: 🇺🇸
Whitman-Walker Clinic, Washington, D.C., District of Columbia, United States
🇺🇸
Orlando Immunology Center, Orlando, Florida, United States
🇺🇸
CARE-ID, Washington, D.C., District of Columbia, United States

and more 4 locations

An Evaluation of Pentoxifylline in HIV-Positive Persons With Symptomatic HIV Infection and a Karnofsky Score > 40 Percent and < 100 Percent

Not Applicable

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Community Research Initiative of New England

Target Recruit Count: 60

Registration Number: NCT00002091

Locations: 🇺🇸
CRI of New England, Brookline, Massachusetts, United States

A Study to Evaluate the Effect of Cimetidine on CD4 Lymphocyte Counts in HIV Infection

Not Applicable

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Community Research Initiative of New England

Registration Number: NCT00002092

Locations: 🇺🇸
CRI of New England, Brookline, Massachusetts, United States

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy